{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-016160","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.869484+00:00","generated_at":"2026-06-04T05:53:30.625253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Femasys FY23 net loss $14.25M, sales down 11%; FemaSeed FDA clearance and positive trial data","bullets":["Net loss $14.25M ($0.93/share) vs $11.39M ($0.96/share) in FY22; sales $1.07M (-11% YoY).","FDA cleared FemaSeed for infertility; pivotal trial showed 24% pregnancy rate in severe male factor cohort.","Cash $21.7M expected to fund operations into 2H 2025; convertible notes of $4.26M issued.","Appointed Richard Spector as CCO and James Liu as CMO.","FemBloc permanent birth control trial enrollment initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-016160","json":"https://secwatch.observer/filing/0001140361-24-016160.json","markdown":"https://secwatch.observer/filing/0001140361-24-016160.md","text":"https://secwatch.observer/filing/0001140361-24-016160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/ef20025488_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:53:30.625253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49537b7b39b6cebf15fe5283d9928cb53ef70d25","claim":"FEMASYS INC reported year ended December 31, 2023 results: net income Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders.","evidence_excerpt":"Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fb15bbb67e1b6bc87d05403c0b85060a63f8f18b","claim":"FEMASYS INC reported year ended December 31, 2022 results: net income net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders.","evidence_excerpt":"Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124016160/0001140361-24-016160-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Net income","value":"net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}